Ironwood Pharmaceuticals Inc (IRWD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ironwood Pharmaceuticals Inc (IRWD) has a cash flow conversion efficiency ratio of -0.360x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($58.28 Million) by net assets ($-161.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IRWD market cap overview for the company's overall valuation and market capitalisation.
Ironwood Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Ironwood Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ironwood Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ironwood Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Ironwood Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Argus Shanghai Textile Chemicals Co Ltd
SHG:603790
|
0.021x |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
0.111x |
|
Addnode Group AB (publ)
ST:ANOD-B
|
0.022x |
|
Delta Israel Brands Ltd
TA:DLTI
|
0.164x |
|
Phenix Optical Co Ltd
SHG:600071
|
0.083x |
|
Aba Chemicals Corp
SHE:300261
|
0.011x |
|
Zhiyang Innovation Technology Co. Ltd. A
SHG:688191
|
-0.026x |
|
Mama's Creations Inc.
NASDAQ:MAMA
|
0.041x |
Annual Cash Flow Conversion Efficiency for Ironwood Pharmaceuticals Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Ironwood Pharmaceuticals Inc from 2007 to 2025. View Ironwood Pharmaceuticals Inc (IRWD) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-261.83 Million | $127.04 Million | -0.485x | -41.20% |
| 2024-12-31 | $-301.33 Million | $103.55 Million | -0.344x | +35.12% |
| 2023-12-31 | $-346.30 Million | $183.43 Million | -0.530x | -226.22% |
| 2022-12-31 | $652.38 Million | $273.76 Million | 0.420x | -2.91% |
| 2021-12-31 | $605.91 Million | $261.89 Million | 0.432x | -83.96% |
| 2020-12-31 | $62.64 Million | $168.84 Million | 2.695x | +2443.52% |
| 2019-12-31 | $-93.25 Million | $10.72 Million | -0.115x | -131.86% |
| 2018-12-31 | $-196.37 Million | $-70.88 Million | 0.361x | +103.57% |
| 2017-12-31 | $9.85 Million | $-99.56 Million | -10.110x | -2552.05% |
| 2016-12-31 | $66.72 Million | $-25.43 Million | -0.381x | +66.09% |
| 2015-12-31 | $95.12 Million | $-106.93 Million | -1.124x | +36.02% |
| 2014-12-31 | $88.55 Million | $-155.57 Million | -1.757x | +75.43% |
| 2013-12-31 | $38.23 Million | $-273.36 Million | -7.151x | -1379.39% |
| 2012-12-31 | $144.05 Million | $-69.63 Million | -0.483x | +29.42% |
| 2011-12-31 | $109.86 Million | $-75.24 Million | -0.685x | -60.93% |
| 2010-12-31 | $159.55 Million | $-67.90 Million | -0.426x | -3275.65% |
| 2009-12-31 | $-298.34 Million | $-4.00 Million | 0.013x | -89.05% |
| 2008-12-31 | $-230.41 Million | $-28.20 Million | 0.122x | +222.94% |
| 2007-12-31 | $-178.37 Million | $-6.76 Million | 0.038x | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well … Read more